Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
|Videos|February 17, 2015
The Development of Biomarkers in Lung Cancer
Author(s)Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.
Advertisement
Clinical Pearls
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.
- Every tumor has a different driver. The point has been reached where combinations seem to be future.
- Developing appropriate drug combinations is challenging, partly because of toxicity.
- There remains a need to further understand tumor biology to target it more specifically.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
Durability of PFS and OS Benefit vs. Historical Control
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5